Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 6 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 14458
Sealed predictions
- MYO1C in dopamine neurons, braak-0.42 (p 0.255) → -0.33 (p 0.386)receipt 14465
Swarm cases
receipt 14465: MYO1C in dopamine neurons, braak
- power
- full sample -0.29 (p 0.239, n 18), 95% CI -0.67 to +0.20. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.34 (p 0.161, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.47 (p 0.050, n 18). not the mix.
- skeptic
- leave-one-out range -0.40 to -0.20, sign flips 0; without severely affected donors -0.29 (p 0.239, n 18). fragile.
- cell type
- strongest in microglia: -0.66 (p 0.0029, n 18) vs -0.29 in dopamine neurons. proposing microglia.
- axis
- no measure beats "tracks Braak Lewy-body stage" for MYO1C in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up MYO1C · microglia · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.03 p 0.929 (needs p < 1.6e-4)
Receipts
loading the receipts